Array Biopharma Inc (NASDAQ:ARRY) insider Victor Sandor sold 156,016 shares of the company’s stock in a transaction on Friday, March 9th. The shares were sold at an average price of $17.71, for a total transaction of $2,763,043.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of NASDAQ:ARRY traded down $1.06 during mid-day trading on Monday, reaching $15.26. 2,799,628 shares of the company were exchanged, compared to its average volume of 3,895,400. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.17 and a current ratio of 6.17. The stock has a market capitalization of $3,388.63, a P/E ratio of -21.19 and a beta of 1.73. Array Biopharma Inc has a 1 year low of $6.73 and a 1 year high of $18.78.
Array Biopharma (NASDAQ:ARRY) last posted its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.06. Array Biopharma had a negative net margin of 98.51% and a negative return on equity of 107.79%. The firm had revenue of $42.21 million during the quarter, compared to analysts’ expectations of $26.81 million. During the same quarter last year, the company posted ($0.14) EPS. The firm’s quarterly revenue was down 5.2% on a year-over-year basis. research analysts forecast that Array Biopharma Inc will post -0.88 earnings per share for the current fiscal year.
Hedge funds have recently modified their holdings of the business. BVF Inc. IL boosted its position in Array Biopharma by 35.7% in the 4th quarter. BVF Inc. IL now owns 8,686,498 shares of the biopharmaceutical company’s stock valued at $111,187,000 after buying an additional 2,283,973 shares during the period. Eversept Partners LLC acquired a new stake in shares of Array Biopharma in the 4th quarter valued at $15,844,000. Dupont Capital Management Corp raised its holdings in shares of Array Biopharma by 20.1% in the 4th quarter. Dupont Capital Management Corp now owns 53,693 shares of the biopharmaceutical company’s stock valued at $687,000 after purchasing an additional 8,987 shares in the last quarter. American International Group Inc. raised its holdings in shares of Array Biopharma by 15.9% in the 4th quarter. American International Group Inc. now owns 134,107 shares of the biopharmaceutical company’s stock valued at $1,717,000 after purchasing an additional 18,401 shares in the last quarter. Finally, Swiss National Bank raised its holdings in shares of Array Biopharma by 13.1% in the 3rd quarter. Swiss National Bank now owns 302,400 shares of the biopharmaceutical company’s stock valued at $3,720,000 after purchasing an additional 35,000 shares in the last quarter. 96.41% of the stock is owned by institutional investors.
ARRY has been the subject of a number of analyst reports. Leerink Swann upgraded shares of Array Biopharma from a “market perform” rating to an “outperform” rating in a research report on Monday, January 22nd. BidaskClub downgraded shares of Array Biopharma from a “hold” rating to a “sell” rating in a research report on Wednesday, March 21st. SunTrust Banks restated a “buy” rating and set a $20.00 price target on shares of Array Biopharma in a research report on Tuesday, February 6th. Jefferies Group increased their price objective on shares of Array Biopharma to $13.00 and gave the company a “buy” rating in a report on Friday, December 22nd. Finally, Stifel Nicolaus increased their price objective on shares of Array Biopharma from $15.00 to $20.00 and gave the company a “buy” rating in a report on Monday, January 22nd. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $16.43.
ILLEGAL ACTIVITY NOTICE: “Array Biopharma Inc (NASDAQ:ARRY) Insider Sells $2,763,043.36 in Stock” was originally posted by Enterprise Leader and is owned by of Enterprise Leader. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://theenterpriseleader.com/2018/04/02/victor-sandor-sells-156016-shares-of-array-biopharma-inc-nasdaqarry-stock.html.
Array Biopharma Company Profile
Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC).
Receive News & Ratings for Array Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.